Literature DB >> 21873591

Multidimensional profiling of CSF1R screening hits and inhibitors: assessing cellular activity, target residence time, and selectivity in a higher throughput way.

Joost C M Uitdehaag1, Cecile M Sünnen, Antoon M van Doornmalen, Nikki de Rouw, Arthur Oubrie, Rita Azevedo, Michael Ziebell, Elliott Nickbarg, Willem-Jan Karstens, Simone Ruygrok.   

Abstract

Over the past years, improvements in high-throughput screening (HTS) technology and compound libraries have resulted in a dramatic increase in the amounts of good-quality screening hits, and there is a growing need for follow-on hit profiling assays with medium throughput to further triage hits. Here the authors present such assays for the colony-stimulating factor 1 receptor (CSF1R, Fms), including tests for cellular activity and a homogeneous assay to measure affinity for inactive CSF1R. They also present a high-throughput assay to measure target residence time, which is based on competitive binding kinetics. To better fit k(off) rates, they present a modified mathematical model for competitive kinetics. In all assays, they profiled eight reference inhibitors (imatinib, sorafenib, sunitinib, tandutinib, dasatinib, GW2580, Ki20227, and J&J's pyrido[2,3-d]pyrimidin-5-one). Using the known biochemical selectivities of these inhibitors, which can be quantified using metrics such as the selectivity entropy, the authors have determined which assay readout best predicts hit selectivity. Their profiling shows surprisingly that imatinib has a preference for the active form of CSF1R and that Ki20227 has an unusually slow target dissociation rate. This confirms that follow-on hit profiling is essential to ensure that the best hits are selected for lead optimization.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21873591     DOI: 10.1177/1087057111418113

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  5 in total

1.  A [(32)P]NAD(+)-based method to identify and quantitate long residence time enoyl-acyl carrier protein reductase inhibitors.

Authors:  Weixuan Yu; Carla Neckles; Andrew Chang; Gopal Reddy Bommineni; Lauren Spagnuolo; Zhuo Zhang; Nina Liu; Christina Lai; James Truglio; Peter J Tonge
Journal:  Anal Biochem       Date:  2015-02-14       Impact factor: 3.365

Review 2.  A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.

Authors:  Joost C M Uitdehaag; Folkert Verkaar; Husam Alwan; Jos de Man; Rogier C Buijsman; Guido J R Zaman
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

3.  CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves.

Authors:  Anna Martínez-Muriana; Renzo Mancuso; Isaac Francos-Quijorna; Adrian Olmos-Alonso; Rosario Osta; V Hugh Perry; Xavier Navarro; Diego Gomez-Nicola; Ruben López-Vales
Journal:  Sci Rep       Date:  2016-05-13       Impact factor: 4.379

4.  Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain.

Authors:  Katharine Askew; Kaizhen Li; Adrian Olmos-Alonso; Fernando Garcia-Moreno; Yajie Liang; Philippa Richardson; Tom Tipton; Mark A Chapman; Kristoffer Riecken; Sol Beccari; Amanda Sierra; Zoltán Molnár; Mark S Cragg; Olga Garaschuk; V Hugh Perry; Diego Gomez-Nicola
Journal:  Cell Rep       Date:  2017-01-10       Impact factor: 9.423

5.  Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology.

Authors:  Adrian Olmos-Alonso; Sjoerd T T Schetters; Sarmi Sri; Katharine Askew; Renzo Mancuso; Mariana Vargas-Caballero; Christian Holscher; V Hugh Perry; Diego Gomez-Nicola
Journal:  Brain       Date:  2016-01-08       Impact factor: 13.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.